Fig. 4.
Frequency of Treg subsets in the clinical course of patients with HNSCC. The percentage of CD4+Foxp3+ cells (a) and CD45RA−Foxp3high Tregs (b) in PBMCs of patients with HNSCC (n = 23) before and after 1 month of standard treatments. The percentage of CD4+Foxp3+ cells (c), CD45RA−Foxp3high Tregs in recurrent cases (d) (n = 6), and CD45RA−Foxp3high Tregs in non-recurrent cases (e) (n = 12) of patients with HNSCC before treatment and after 1 month and 3–6 months of standard treatments. The percentage of CD45RA−Foxp3high Tregs in patients who underwent surgery (f) and chemoradiotherapy (g) before and after treatment. Statistical comparisons were performed using the paired t test. *p < 0.05, **p < 0.01, ***p < 0.001. n.s. not significant, M month